Literature DB >> 11264180

Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination.

A Stucki1, A S Rivier, M Gikic, N Monai, M Schapira, O Spertini.   

Abstract

Leukostasis and tissue infiltration by leukemic cells are poorly understood life-threatening complications of acute leukemia. This study has tested the hypothesis that adhesion receptors and cytokines secreted by blast cells play central roles in these reactions. Immunophenotypic studies showed that acute myeloid leukemia (AML) cells (n = 78) of the M0 to M5 subtypes of the French-American-British Cooperative Group expressed various amounts of adhesion receptors, including CD11a, b, c/CD18, CD49d, e, f/CD29, CD54, sCD15, and L-selectin. The presence of functional adhesion receptors was evaluated using a nonstatic adhesion assay. The number of blast cells attached to unactivated endothelium increased by 7 to 31 times after a 6-hour exposure of endothelium to tumor necrosis factor (TNF)-alpha. Inhibition studies showed that multiple adhesion receptors--including L-selectin, E-selectin, VCAM-1, and CD11/CD18--were involved in blast cell adhesion to TNF-alpha-activated endothelium. Leukemic cells were then cocultured at 37 degrees C on unactivated endothelial cell monolayers for time periods up to 24 hours. A time-dependent increase in the number of blasts attached to the endothelium and a concomitant induction of ICAM-1, VCAM-1, and E-selectin were observed. Additional experiments revealed that endothelial cell activation by leukemic myeloblasts was caused by cytokine secretion by blast cells, in particular TNF-alpha and IL-1 beta, and direct contacts between adhesion receptors expressed by blast cells and endothelial cells. Thus, leukemic cells have the ability to generate conditions that promote their own adhesion to vascular endothelium, a property that may have important implications for the pathophysiology of leukostasis and tissue infiltration by leukemic blast cells. (Blood. 2001;97:2121-2129)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264180     DOI: 10.1182/blood.v97.7.2121

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Leukemia regression by vascular disruption and antiangiogenic therapy.

Authors:  Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 2.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

3.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

4.  Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.

Authors:  Vindhya Vijay; Regan Miller; Gau Shoua Vue; Mida Bahareh Pezeshkian; Michael Maywood; Allison M Ast; Leylah M Drusbosky; Yuri Pompeu; Alan D Salgado; Samuel D Lipten; Timothy Geddes; Ann Marie Blenc; Yubin Ge; David A Ostrov; Christopher R Cogle; Gerard J Madlambayan
Journal:  Leuk Res       Date:  2019-07-03       Impact factor: 3.156

5.  Fatal Cerebral Leucostasis in Acute Leukaemia with Hyperleucocytosis.

Authors:  S K Magu; A K Malviya
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 6.  Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Authors:  Shaheedul A Sami; Noureldien H E Darwish; Amanda N M Barile; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2020-01-13

7.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Roland B Walter; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Franklin O Smith; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Janet L Franklin; Craig A Hurwitz; Michael R Loken; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

8.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.

Authors:  Jeffrey A Knight; Andrew D Skol; Abhijit Shinde; Darcie Hastings; Richard A Walgren; Jin Shao; Thelma R Tennant; Mekhala Banerjee; James M Allan; Michelle M Le Beau; Richard A Larson; Timothy A Graubert; Nancy J Cox; Kenan Onel
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

9.  Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil.

Authors:  L C O Oliveira; L G M Romano; B P A Prado-Junior; D T Covas; E M Rego; G C De Santis
Journal:  Med Oncol       Date:  2009-11-25       Impact factor: 3.064

10.  Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia.

Authors:  Kristina Hölig; Rainer Moog
Journal:  Transfus Med Hemother       Date:  2012-07-26       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.